Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Provided By GlobeNewswire
Last update: Oct 31, 2025
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA
Read more at globenewswire.comNASDAQ:ADAG (11/14/2025, 8:00:00 PM)
1.83
+0.03 (+1.67%)
Find more stocks in the Stock Screener
